Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma.
Naito S, Ichiyanagi O, Kato T, Kanno H, Narisawa T, Kurokawa M, Ushijima M, Ozawa M, Yagi M, Kurota Y, Fukuhara H, Yamagishi A, Sakurai T, Nishida H, Kawazoe H, Yamanobe T, Tsuchiya N.
Naito S, et al. Among authors: sakurai t.
Sci Rep. 2019 Oct 29;9(1):15451. doi: 10.1038/s41598-019-51305-7.
Sci Rep. 2019.
PMID: 31664053
Free PMC article.